marijuana stock news

INSYS Therapeutics to Report Second Quarter 2018 Results on Aug. 8

INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its second quarter 2018 financial results on Wednesday, Aug. 8, after the U.S. financial markets close.

Following the release, Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial officer, will host a conference call at 5:00 p.m. Eastern Daylight Time to discuss the results.

Interested parties can listen to the call live as it occurs via the company’s website, https://www.insysrx.com/, on the Investors section’s Presentations & Events page; or by dialing 844-263-8304 (from inside the U.S.) or 213-358-0958 (from outside the U.S.) and using the Conference ID 2070039. A webcasted replay of the call will be available on the site a few hours after the event.

About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$CBDS Income Statement

Cannabis Sativa, Inc. (CBDS) Income Statement Get Income Statement for: View: Annual…

MustGrow Biologics Corp. (MGROF) and Bayer Sign Commercial License Agreement for Biocontrol Technologies in Europe, Middle East and Africa

MustGrow Biologics and Bayer Sign Commercial License Agreement for Biocontrol Technologies in…

Neptune Wellness Solutions Inc. (NEPT) Announces Receipt of Amendment to its Health Canada License

Neptune Wellness Solutions Inc. Announces Receipt of Amendment to its Health Canada…

Digipath, Inc. (DIGP) Announces Revenue Increase of Almost 18% for the Fourth Quarter of Fiscal Year 2022

Digipath, Inc. Announces Revenue Increase of Almost 18% for the Fourth Quarter…